Back to results
US 12,474,343 B2Granted
Compositions and methods for detecting and treating gastric cancer
AssigneeProgastrine et Cancers S.À R.L.
InventorAlexandre Prieur
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the in vitro diagnosis of gastric cancer, and to compositions and methods for the prevention or the treatment of gastric cancer. Disclosed are compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.
Claims9
A method for inhibiting the proliferation of gastric cancer stem cells in a patient suffering from gastric cancer, said method comprising administering a composition comprising a monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof, to said patient,
- wherein said antigen-binding fragment thereof comprises the 6 complementary determining regions (CDR) of the monoclonal progastrin-binding antibody from which it is derived and wherein said CDRs are defined by international ImMungoGenTics information system (IMGT), and
- wherein said monoclonal progastrin-binding antibody is selected from the group consisting of:
- an antibody comprising a heavy chain (H) comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, and a light chain (L) comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, respectively, and
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:34, SEQ ID NO:35, and SEQ ID NO:36, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively.
5 more elements
A method for inhibiting the proliferation of gastric cancer stem cells in a patient suffering from gastric cancer, said method comprising administering a pharmaceutical composition comprising a monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof, and a pharmaceutically acceptable carrier, to said patient,
- wherein said antigen-binding fragment thereof comprises the 6 complementary determining regions (CDR) of the monoclonal progastrin-binding antibody from which it is derived and wherein said CDRs are defined by the international ImMungoGenTics information system (IMGT), and
- wherein said monoclonal progastrin-binding antibody is selected from the group consisting of:
- an antibody comprising a heavy chain (H) comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, and a light chain (L) comprising CDR-L1, CDR-L2
- and CDR-L3 comprising amino acid sequences SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, respectively,
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, respectively, and
- an antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising amino acid sequences SEQ ID NO:34, SEQ ID NO:35, and SEQ ID NO:36, respectively, and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising amino acid sequences SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively.
6 more elements
Dependencies are inferred from the claim text.